期刊
WORLD JOURNAL OF GASTROINTESTINAL ONCOLOGY
卷 13, 期 8, 页码 772-798出版社
BAISHIDENG PUBLISHING GROUP INC
DOI: 10.4251/wjgo.v13.i8.772
关键词
Immune checkpoint inhibitors; Cytotoxic T-lymphocyte antigen 4; Programmed cell death protein-1; Inflammatory bowel disease; Gastrointestinal cancer
ICI therapy has revolutionized cancer treatment by boosting the immune system against tumors, but it can also lead to autoimmune-like side effects such as IMC. Patients with GI malignancies and pre-existing inflammatory bowel disease are at increased risk of developing IMC.
Immune checkpoint inhibitors (ICI) have markedly changed the landscape of cancer therapy. By re-invigorating the immune system against tumors, ICI provide novel therapeutic options for a broad variety of malignancies, including many gastrointestinal (GI) cancers. However, these therapies can also induce autoimmune-like side effects in healthy tissue across the body. One of the most common of these side effects is ICI-mediated colitis and diarrhea (IMC). Here, we review the incidence and risk of IMC in ICI therapy, with a focus on what is known regarding IMC in patients with GI malignancies. We also discuss data available on the use of ICI and risk of IMC in patients with pre-existing inflammatory bowel disease, as these patients may have increased risk of IMC due to their underlying intestinal pathology.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据